Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added health benefits.

Berkshire Hathaway's diversification, culture, and investment philosophy should still make it a great long-term buy, but investors might have to be patient as the company begins delivering outstanding market-beating returns again. Through 2030, Eli Lilly could outperform it enough to be worth more.

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, revenue from the diabetes drug Mounjaro, which has been on the market longer, has doubled, to $6.52 billion, thanks to growth outside the U.S.

The Michigan Supreme Court heard oral arguments Wednesday in the state attorney general’s case against insulin-maker Eli Lilly and Company.

Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer Eli Lilly and NVIDIA have announced a partnership to build out an AI supercomputer for pharmaceutical research and development.

Food and ⁠Drug ‌Administration to approve ‍its experimental oral obesity drug,​ ‌orforglipron, by March 2026, its ⁠chief executive ​said ​on Thursday. (Reporting ‍by ⁠Kamal Choudhury in Bengaluru;⁠ Editing ‌by Shilpi ‌Majumdar).

Eli Lilly is expanding its Kenosha County campus with plans to construct six new buildings adjacent to the former Nexus Pharmaceuticals site.

Eli Lilly and Company (NYSE:LLY) develops medicines for diabetes, obesity, cancer, autoimmune disorders, and neurological conditions.